Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Republic HealthcareHKSE:08357 30 EBITDA Margin % is -18.31% as of Jun. 2026. GuruFocus rates HKSE:08357 with a GF Score™ of 30/100 and a GF Value™ of HK$0.09 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Republic Healthcare ranks worse than 85.91% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Republic Healthcare's EBITDA for the
six
months ended in Jun. 2026 was HK$-4.63 Mil. Republic Healthcare's Revenue for the
six
months ended in Jun. 2026 was HK$25.26 Mil. Therefore, Republic Healthcare's EBITDA margin for the quarter that ended in Jun. 2026 was -18.31%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Republic Healthcare EBITDA Margin % Related Terms
Republic Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Republic Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08357 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Republic Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Republic Healthcare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Republic Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Republic Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Republic Healthcare (HKSE:08357) has a EBITDA Margin % of -18.31% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Republic Healthcare and its competitors. According to the industry distribution chart, Republic Healthcare ranks #573 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 85.9%.
Is Republic Healthcare's EBITDA Margin % too high?
Republic Healthcare's current EBITDA Margin % is -18.31%. Based on the distribution chart, Republic Healthcare ranks #573 out of 667 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Republic Healthcare has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Republic Healthcare's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Republic Healthcare ranks #573 out of 667 companies for EBITDA Margin %. This places Republic Healthcare in the lower half of its industry. The industry median EBITDA Margin % is 10.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Republic Healthcare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Republic Healthcare's current EBITDA Margin % is -18.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Republic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Republic Healthcare (HKSE:08357) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.09, compared to a current price of HK$0.10 — trading 14.4% above its estimated fair value. The current EBITDA Margin % is -18.31%. Republic Healthcare's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Republic Healthcare (HKSE:08357), the current EBITDA Margin % is -18.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Republic Healthcare (HKSE:08357) Overvalued in 2026?
Based on GuruFocus' analysis, Republic Healthcare stock appears to be overvalued.
The current stock price of HK$0.10 is trading 14.4% above its estimated GF Value™ of HK$0.09.
GuruFocus considers Republic Healthcare to be Modestly Overvalued.
Key valuation signals for HKSE:08357:
EBITDA Margin %: -18.31%
GF Value™: HK$0.09 vs. price of HK$0.10 (14.4% above fair value)
No single metric tells the full story. See the HKSE:08357 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Republic Healthcare Ltd is principally engaged in the clinic business in Singapore and the provision of management advisory services. The company provides healthcare services operating a network of general practice clinics, treatment solutions for common medical conditions with a focus on sexual health and infectious diseases, and operation of a medical aesthetics clinic that focuses on providing treatment solutions for common skin conditions and basic medical aesthetics services. The company is segments are medical services and education services. The Group is engaged in the operation of medical clinics and the provision of management advisory services, pepper trading business, and healthcare-related education business. It generates maximum revenue from Singapore.
30GF Score
Get the complete analysis for HKSE:08357
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08357 has been successfully added to your 
